Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 2
1982 5
1983 4
1984 1
1985 4
1986 4
1987 3
1988 6
1989 5
1990 14
1991 12
1992 13
1993 16
1994 18
1995 25
1996 23
1997 23
1998 33
1999 29
2000 47
2001 52
2002 43
2003 69
2004 79
2005 94
2006 109
2007 153
2008 168
2009 173
2010 221
2011 309
2012 339
2013 413
2014 456
2015 602
2016 613
2017 715
2018 765
2019 978
2020 1060
2021 1269
2022 1047
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

8,985 results
Results by year
Filters applied: . Clear all
Page 1
Design of protein-binding proteins from the target structure alone.
Cao L, Coventry B, Goreshnik I, Huang B, Sheffler W, Park JS, Jude KM, Marković I, Kadam RU, Verschueren KHG, Verstraete K, Walsh STR, Bennett N, Phal A, Yang A, Kozodoy L, DeWitt M, Picton L, Miller L, Strauch EM, DeBouver ND, Pires A, Bera AK, Halabiya S, Hammerson B, Yang W, Bernard S, Stewart L, Wilson IA, Ruohola-Baker H, Schlessinger J, Lee S, Savvides SN, Garcia KC, Baker D. Cao L, et al. Nature. 2022 May;605(7910):551-560. doi: 10.1038/s41586-022-04654-9. Epub 2022 Mar 24. Nature. 2022. PMID: 35332283 Free PMC article.
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group. Wang J, et al. Among authors: cao l. Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576956 Clinical Trial.
A Purple Liver.
Jiang G, Pu X, Cao L. Jiang G, et al. Among authors: cao l. Clin Gastroenterol Hepatol. 2022 Jun 16:S1542-3565(22)00564-X. doi: 10.1016/j.cgh.2022.05.036. Online ahead of print. Clin Gastroenterol Hepatol. 2022. PMID: 35716903 No abstract available.
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y, Liu C, Zhu S, Zhang X, Li Y, Liu J, Cao L, Cheng Y, Zhao H, Zhang S, Zang A, Cui J, Feng J, Yang N, Liu F, Jiang Y, Gu C; FURLONG investigators. Shi Y, et al. Among authors: cao l. Lancet Respir Med. 2022 Jun 2:S2213-2600(22)00168-0. doi: 10.1016/S2213-2600(22)00168-0. Online ahead of print. Lancet Respir Med. 2022. PMID: 35662408
AI in Combating the COVID-19 Pandemic.
Cao L. Cao L. IEEE Intell Syst. 2022 May 20;37(2):3-13. doi: 10.1109/MIS.2022.3164313. eCollection 2022 Mar. IEEE Intell Syst. 2022. PMID: 35935446 Free PMC article.
Research Advances on Matrine.
Sun XY, Jia LY, Rong Z, Zhou X, Cao LQ, Li AH, Guo M, Jin J, Wang YD, Huang L, Li YH, He ZJ, Li L, Ma RK, Lv YF, Shao KK, Zhang J, Cao HL. Sun XY, et al. Among authors: cao lq. Front Chem. 2022 Apr 1;10:867318. doi: 10.3389/fchem.2022.867318. eCollection 2022. Front Chem. 2022. PMID: 35433636 Free PMC article. Review.
8,985 results